- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04498078
Creatine Supplementation in Autism Spectrum Disorder (CREATOR)
February 5, 2024 updated by: University of Novi Sad, Faculty of Sport and Physical Education
The Effects of Creatine Supplementation in Autism Spectrum Disorder: a Randomized Placebo-controlled Trial
Autism Spectrum Disorder (ASD) is accompanied by reduced levels of total creatine in right temporal-parietal junction and other brain regions of interest, and addressing this deficit by exogenous administration of creatine may have beneficial effects on brain metabolism and disease-specific clinical symptoms in patients suffering from ASD.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Vojvodina
-
Novi Sad, Vojvodina, Serbia, 21000
- FSPE Applied Bioenergetics Lab
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 10 years and above
- Informed consent signed by a parent or legal guardian or legal representative
- Diagnostic and Statistical Manual of Mental Disorders-IV criteria for ASD.
Exclusion Criteria:
- Pregnant or nursing female patients
- Non-pharmacologic therapy
- Current diagnosis of other mental disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Creatine
Twenty grams per day b.i.d.
|
Creatine monohydrate (20 g per day)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain creatine change
Time Frame: Change from Baseline Brain Creatine Levels at 6 Months
|
Monitor change in brain creatine levels by magnetic resonance imaging
|
Change from Baseline Brain Creatine Levels at 6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain N-acetylaspartate change
Time Frame: Change from Baseline Brain N-acetylaspartate Levels at 6 Months
|
Monitor change in brain N-acetylaspartate levels by magnetic resonance imaging
|
Change from Baseline Brain N-acetylaspartate Levels at 6 Months
|
Autism Treatment Evaluation Checklist (ATEC) score
Time Frame: Change from Baseline ATEC Scores at 6 Months
|
Monitor changes in ASD severity
|
Change from Baseline ATEC Scores at 6 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities
Time Frame: Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities at 6-Month Follow-up
|
Abnormal metabolic criterion values include fasting serum aspartate aminotransferase ≥ 40 U/L, fasting serum alanine aminotransferase ≥ 56 U/L, fasting serum gamma-glutamyl transferase ≥ 48 U/L
|
Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities at 6-Month Follow-up
|
Maximal oxygen uptake change
Time Frame: Change from Baseline Cardiorespiratory Capacity at 6 Months
|
Monitor changes in maximal oxygen uptake during an incremental exercise test on a treadmill
|
Change from Baseline Cardiorespiratory Capacity at 6 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Nebojsa Maksimovic, PhD, Faculty of Sport and PE
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2022
Primary Completion (Estimated)
January 15, 2025
Study Completion (Estimated)
February 14, 2025
Study Registration Dates
First Submitted
July 27, 2020
First Submitted That Met QC Criteria
July 30, 2020
First Posted (Actual)
August 4, 2020
Study Record Updates
Last Update Posted (Actual)
February 6, 2024
Last Update Submitted That Met QC Criteria
February 5, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABL-21-AUCR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized data will be provide via institutional online depository
IPD Sharing Time Frame
From January 2022 to December 2022
IPD Sharing Access Criteria
Free access
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on Creatine
-
Texas A&M UniversityNutraboltCompletedDietary Modification
-
University of Novi Sad, Faculty of Sport and Physical...Completed
-
GlaxoSmithKlineCompletedSports Nutritional SciencesUnited Kingdom
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Texas A&M UniversityNutraboltCompletedDietary Supplementation
-
Dynamical Business and Science Society - DBSS International...CES University; INDEPORTES AntioquiaCompleted
-
The Cleveland ClinicCompletedHypercholesterolemia | Weakness | Cramps | AchesUnited States
-
Silesian Centre for Heart DiseasesRecruiting
-
University of UtahNational Cancer Institute (NCI)RecruitingFatigue | Sedentary Lifestyle | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVB Prostate Cancer AJCC (American Joint Committee on Cancer) v8United States
-
Beth Israel Medical CenterCompleted